Imaging With a PET Agent for Detection of Cancers of the Head and Neck
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/22/2019 |
| Start Date: | August 10, 2018 |
| End Date: | August 2020 |
| Contact: | Heiko Schöder, MD |
| Email: | schoderh@mskcc.org |
| Phone: | 212-639-2079 |
Safety, Biodistribution and Radiation Dosimetry of [18F]PARPi
The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug
has been tested in animals but not yet in people. The purpose of this study is to test if a
PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to
imaging this cancer includes several different imaging scans, including x-rays, CT (computed
tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These
tests take pictures of the cancer.
has been tested in animals but not yet in people. The purpose of this study is to test if a
PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to
imaging this cancer includes several different imaging scans, including x-rays, CT (computed
tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These
tests take pictures of the cancer.
Inclusion Criteria:
- Age ≥18 years
- ECOG performance status 0 or 1
- Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma
- Oral cavity, oropharynx, or nasopharynx primary site
- At least one tumor lesion on standard of care imaging with a minimum diameter of at
least 1.5 cm
- Scheduled to undergo treatment at MSKCC
- Willingness to sign informed consent
Exclusion Criteria:
- Significantly impaired organ function that may interfere with the excretion and
metabolism of the imaging agent. Specifically, patients will be excluded if they meet
the following criteria:
- Hematologic
o Platelets <75K/mcL
- Hepatic
- Bilirubin >2.0 x ULN (institutional upper limits of normal)
- AST/ALT >2.5 x ULN
- Renal
o Creatinine > 2.0 x ULN
- Claustrophobia interfering with PET/CT imaging
- Known allergy to PEG300
- Pregnancy or breastfeeding
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-2079
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
